Picroside II promotes HSC apoptosis and inhibits the cholestatic liver fibrosis in Mdr2^−/− mice by polarizing M1 macrophages and balancing immune responses

Abstract

Liver fibrosis is characterized by chronic inflammatory responses and progressive fibrous scar formation. Macrophages play a central role in the pathogenesis of hepatic fibrosis by reconstructing the immune microenvironment. Picroside II (PIC II), extracted from Picrorhizae Rhizoma, has demonstrated therapeutic potential for various liver damage. However, the mechanisms by which macrophage polarization initiates immune cascades and contributes to the development of liver fibrosis, and whether this process can be influenced by PIC II, remain unclear. In the current study, RNA sequencing and multiple molecular approaches were utilized to explore the underlying mechanisms of PIC II against liver fibrosis in multidrug-resistance protein 2 knockout (Mdr2^−/−) mice. Our findings indicate that PIC II activates M1-polarized macrophages to recruit natural killer cells (NK cells), potentially via the CXCL16-CXCR6 axis. Additionally, PIC II promotes the apoptosis of activated hepatic stellate cells (aHSCs) and enhances the cytotoxic effects of NK cells, while also reducing the formation of neutrophil extracellular traps (NETs). Notably, the anti-hepatic fibrosis effects associated with PIC II were largely reversed by macrophage depletion in Mdr2^−/− mice. Collectively, our research suggests that PIC II is a potential candidate for halting the progression of liver fibrosis.

Keywords

Liver fibrosis / Picroside II / M1 macrophage / Hepatic stellate cell / Natural killer cell / Neutrophil

References

[1] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55.

[2] Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 633-646.

[3] Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 306-315.

[4] Liu Y, Chen K, Li F, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice[J]. Hepatology, 2020, 71(6): 2050-2066.

[5] Zhang J, Lyu Z, Li B, et al. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases[J]. Hepatology, 2023, 78(1): 10-25.

[6] Liu R, Li X, Zhu W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis[J]. Hepatology, 2019, 70(4): 1317-1335.

[7] Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-β delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice[J]. Gastroenterology, 2014, 147(6): 1378-1392.

[8] Guicciardi ME, Trussoni CE, Krishnan A, et al. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice[J]. J Hepatol, 2018, 69(3): 676-686.

[9] Shi T, Malik A, Yang VH, et al. Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis[J]. Sci Transl Med, 2022, 14(675): eabi4354.

[10] Greenman R, Segal-Salto M, Barashi N, et al. CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis[J]. JCI Insight, 2023, 8(12): e162270.

[11] Ravichandran G, Neumann K, Berkhout LK, et al. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice[J]. J Hepatol, 2019, 71(4): 773-782.

[12] Taylor AE, Carey AN, Kudira R, et al. Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis[J]. Hepatology, 2018, 68(5): 1905-1921.

[13] Li T, Xu L, Zheng R, et al. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor[J]. Phytomedicine, 2020, 68: 153153.

[14] Ma S, Wang X, Lai F, et al. The beneficial pharmacological effects and potential mechanisms of picroside II: evidence of its benefits from in vitro and in vivo[J]. Biomed Pharmacother, 2020, 130: 110421.

[15] Duan S, Li X, Fan G, et al. Targeting bile acid signaling for the treatment of liver diseases: from bench to bed[J]. Biomed Pharmacother, 2022, 152: 113154.

[16] Huang Y, Zhou M, Li C, et al. Picroside II protects against sepsis via suppressing inflammation in mice[J]. Am J Transl Res, 2016, 8(12): 5519-5531.

[17] Wang Y, Hong Y, Zhang C, et al. Picroside II attenuates hyperhomocysteinemia-induced endothelial injury by reducing inflammation, oxidative stress and cell apoptosis[J]. J Cell Mol Med, 2019, 23(1): 464-475.

[18] Li Y J, Liu RP, Ding MN, et al. Tetramethylpyrazine prevents liver fibrotic injury in mice by targeting hepatocyte-derived and mitochondrial DNA-enriched extracellular vesicles[J]. Acta Pharmacol Sin, 2022, 43(8): 2026-2041.

[19] Sliz A, Locker KCS, Lampe K, et al. Gab3 is required for IL-2- and IL-15-induced NK cell expansion and limits trophoblast invasion during pregnancy[J]. Sci Immunol, 2019, 4(38): eaav3866.

[20] Fehniger TA, Carson WE, Mrózek E, et al. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo[J]. Blood, 1997, 90(9): 3647-3653.

[21] Melhem A, Muhanna N, Bishara A, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC[J]. J Hepatol, 2006, 45(1): 60-71.

[22] Casini A, Ceni E, Salzano R, et al. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide[J]. Hepatology, 1997, 25(2): 361-367.

[23] Zhou Z, Xu MJ, Cai Y, et al. Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis[J]. Cell Mol Gastroenterol Hepatol, 2018, 5(3): 399-413.

[24] Cheng D, Chai J, Wang H, et al. Hepatic macrophages: key players in the development and progression of liver fibrosis[J]. Liver Int, 2021, 41(10): 2279-2294.

[25] Ma PF, Gao CC, Yi J, et al. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice[J]. J Hepatol, 2017, 67(4): 770-779.

[26] Martí-Rodrigo A, Alegre F, Moragrega ÁB, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5): 920-932.

[27] Li YW, Lu YR, Nian MZ, et al. Therapeutic potential and mechanism of Chinese herbal medicines in treating fibrotic liver disease[J]. Chin J Nat Med, 2023, 21(9): 643-657.

[28] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166.

[29] Tacke F. Targeting hepatic macrophages to treat liver diseases[J]. J Hepatol, 2017, 66(6): 1300-1312.

[30] Rao J, Wang H, Ni M, et al. FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2[J]. Gut, 2022, 71(12): 2539-2550.

[31] Korbecki J, Bajdak-Rusinek K, Kupnicka P, et al. The role of CXCL16 in the pathogenesis of cancer and other diseases[J]. Int J Mol Sci, 2021, 22(7): 3490.

[32] Mossanen JC, Kohlhepp M, Wehr A, et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4⁽⁺⁾ T-cell-dependent control of senescence[J]. Gastroenterology, 2019, 156(6): 1877-1889.e4.

[33] Xu HB, Gong YP, Cheng J, et al. CXCL16 participates in pathogenesis of immunological liver injury by regulating T lymphocyte infiltration in liver tissue[J]. World J Gastroenterol, 2005, 11(32): 4979-4985.

[34] Liepelt A, Wehr A, Kohlhepp M, et al. CXCR6 protects from inflammation and fibrosis in NEMO(LPC-KO) mice[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(2): 391-402.

[35] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(7): 397-411.

[36] Choi WM, Ryu T, Lee JH, et al. Metabotropic glutamate receptor 5 in natural killer cells attenuates liver fibrosis by exerting cytotoxicity to activated stellate cells[J]. Hepatology, 2021, 74(4): 2170-2185.

[37] Chigbu DI, Loonawat R, Sehgal M, et al. Hepatitis C virus infection: host-virus interaction and mechanisms of viral persistence[J]. Cells, 2019, 8(4): E376.

[38] Wen J, Zhou Y, Wang J, et al. Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN-γ/STAT1 pathway[J]. Cell Death Differ, 2017, 24(6): 997-1006.

[39] Guo M, Wang Z, Dai J, et al. Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway[J]. Phytomedicine, 2022, 112: 154587.

[40] Li T, Zheng R, Xu L, et al. Picroside II alleviates liver injury induced by alpha-naphthylisothiocyanate through AMPK-FXR pathway[J]. Toxicol Appl Pharmacol, 2020, 408: 115248.

[41] Li M, Zhang X, Lu Y, et al. The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines[J]. Cell Death Dis, 2020, 11(1): 31.

[42] Wu J, Zhang C, He T, et al. Polyunsaturated fatty acids drive neutrophil extracellular trap formation in nonalcoholic steatohepatitis[J]. Eur J Pharmacol, 2023, 945: 175618.

[43] Scozzi D, Gelman AE. Avoid being trapped by your liver: ischemia-reperfusion injury in liver transplant triggers S1P-mediated NETosis[J]. J Clin Invest, 2023, 133(3): e167012.

[44] Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated by the microbiome[J]. Nature, 2015, 525(7570): 528-532.

[45] Tian X, Wang Y, Lu Y, et al. Conditional depletion of macrophages ameliorates cholestatic liver injury and fibrosis via lncRNA-H19[J]. Cell Death Dis, 2021, 12(7): 646.

[46] Airik M, McCourt B, Ozturk TT, et al. Mitigation of portal fibrosis and cholestatic liver disease in ANKS6-deficient livers by macrophage depletion[J]. FASEB J, 2022, 36(2): e22157.

Funding

National Key Research and Development Program on Modernization of Traditional Chinese Medicine(2022YFC3502100)

National Natural Science Foundation of China(82274186)

National High-Level Talents Special Support Program

Young Talents Promotion Project of China Association of Traditional Chinese Medicine(2020-QNRC2-01)

Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-C-202006)